• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较不适合移植的外周 T 细胞淋巴瘤非特指型和血管免疫母细胞性 T 细胞淋巴瘤患者的预后评分:来自日本国立医院组织的回顾性研究。

Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.

机构信息

Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

Department of Hematology and Oncology Research, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

出版信息

Leuk Lymphoma. 2021 Apr;62(4):819-827. doi: 10.1080/10428194.2020.1845336. Epub 2020 Nov 9.

DOI:10.1080/10428194.2020.1845336
PMID:33167741
Abstract

We retrospectively analyzed the risk factors for outcomes among patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS,  = 100) and angioimmunoblastic T-cell lymphoma (AITL,  = 128) who did not receive hematopoietic stem cell transplantation between 2008 and 2018. We designed a comparison of prognostic scores specifically for PTCL-NOS and AITL. The international prognostic index (IPI) was useful for investigating the risk factors associated with outcomes among transplant-ineligible patients with PTCL-NOS (Harrell's c-statistic 0.715) and AITL (c-statistic 0.615). The prognostic index for T-cell lymphoma (PIT), modified PIT, and the International Peripheral T Cell Lymphoma Project for overall survival (OS) seemed to identify separate prognostic groups, based on visual assessment of Kaplan-Meier curves. However, better c-statistics (>0.7) were only found for the IPI score for OS in PTCL-NOS. Strategies that carefully select PTCL patients with higher IPI scores may help to identify individuals suitable for novel therapies.

摘要

我们回顾性分析了 2008 年至 2018 年间未接受造血干细胞移植的外周 T 细胞淋巴瘤非特指型(PTCL-NOS,n=100)和血管免疫母细胞性 T 细胞淋巴瘤(AITL,n=128)患者的结局相关的危险因素。我们设计了专门针对 PTCL-NOS 和 AITL 的预后评分比较。国际预后指数(IPI)可用于研究不适合移植的 PTCL-NOS(哈雷尔 C 统计量 0.715)和 AITL(C 统计量 0.615)患者结局相关的危险因素。T 细胞淋巴瘤预后指数(PIT)、改良 PIT 和国际外周 T 细胞淋巴瘤项目的总生存(OS)似乎根据 Kaplan-Meier 曲线的视觉评估来识别不同的预后组。然而,仅在 PTCL-NOS 的 OS 中发现 IPI 评分的 C 统计量更高(>0.7)。仔细选择具有更高 IPI 评分的 PTCL 患者的策略可能有助于识别适合新型疗法的个体。

相似文献

1
Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.比较不适合移植的外周 T 细胞淋巴瘤非特指型和血管免疫母细胞性 T 细胞淋巴瘤患者的预后评分:来自日本国立医院组织的回顾性研究。
Leuk Lymphoma. 2021 Apr;62(4):819-827. doi: 10.1080/10428194.2020.1845336. Epub 2020 Nov 9.
2
Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.异质性外周 T 细胞淋巴瘤和血管免疫母细胞性 T 细胞淋巴瘤患者干细胞移植的疗效。
Int J Hematol. 2020 Jul;112(1):74-83. doi: 10.1007/s12185-020-02879-w. Epub 2020 Apr 15.
3
Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma.滤泡辅助 T 细胞淋巴瘤国际预后指数的全面比较。
Ann Hematol. 2022 Jul;101(7):1535-1543. doi: 10.1007/s00277-022-04805-y. Epub 2022 May 31.
4
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.回顾性分析血管免疫母细胞 T 细胞淋巴瘤的预后因素:日本多中心合作研究。
Blood. 2012 Mar 22;119(12):2837-43. doi: 10.1182/blood-2011-08-374371. Epub 2012 Feb 2.
5
Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.外周T细胞淋巴瘤患者自体干细胞移植的危险因素及时机
Int J Hematol. 2019 Feb;109(2):175-186. doi: 10.1007/s12185-018-2560-x. Epub 2018 Nov 14.
6
Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.血清IgA水平、单核细胞计数和国际预后指数与HTLV-I阴性淋巴结外周T细胞淋巴瘤患者的总生存期独立相关。
Ann Hematol. 2014 Jul;93(7):1185-91. doi: 10.1007/s00277-014-2025-0. Epub 2014 Feb 14.
7
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.复发/难治性外周T细胞淋巴瘤(非特殊类型)和血管免疫母细胞性T细胞淋巴瘤患者的生存结局。
Br J Haematol. 2017 Mar;176(5):750-758. doi: 10.1111/bjh.14477. Epub 2016 Dec 16.
8
Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.外周T细胞淋巴瘤(非特指型)预后因素分析及预后评分比较:一项针对105例中国患者的单机构研究
Ann Hematol. 2015 Feb;94(2):239-47. doi: 10.1007/s00277-014-2188-8. Epub 2014 Sep 6.
9
Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.外周 T 细胞淋巴瘤预后因素分析:血清白蛋白和纵隔淋巴结肿大的预后价值。
Leuk Lymphoma. 2009 Dec;50(12):1999-2004. doi: 10.3109/10428190903318311.
10
Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.TBX21、CXCR3、GATA3、CCR4和TCF1免疫组化表达在淋巴结滤泡辅助性T细胞淋巴瘤及外周T细胞淋巴瘤(非特指型)中的临床病理意义
J Pathol Transl Med. 2024 Mar;58(2):59-71. doi: 10.4132/jptm.2024.01.04. Epub 2024 Jan 22.

引用本文的文献

1
Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.罗米地辛作为吉西他滨、地塞米松和顺铂治疗后巩固治疗的II期试验,用于老年移植不适用的复发/难治性外周T细胞淋巴瘤患者。
Hematol Rep. 2024 May 28;16(2):336-346. doi: 10.3390/hematolrep16020034.
2
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.比较真实世界中大型老年人群外周 T 细胞淋巴瘤中 IPI 和 PIT 的预后影响。
Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5.
3
Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.
血管免疫母细胞性 T 细胞淋巴瘤的诊断和治疗进展。
Curr Oncol. 2021 Dec 20;28(6):5480-5498. doi: 10.3390/curroncol28060456.